Abstract: The present invention relates to a vaccine and a method for protecting piglets against PCV-2 infection by administering a vaccine comprising at least 20 micrograms/dose of ORF-2 protein of porcine circovirus type 2, even when they have a relatively high titer of maternally derived antibodies against PCV-2. A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.

Abstract: The present invention relates to a chemically stable formulation of florfenicol, (and structurally related compounds) in compositions such as soluble blended powders, granules, fast-dissolving tablets or pellets suitable for rapid release of the drug in water, and to methods and kits for treating animals with aqueous compositions including florfenicol.

Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

Abstract: A salmonid alphavirus polypeptide comprising an epitope capable of inducing a virus neutralizing immune response, nucleic acids encoding the polypeptide, a vaccine comprising the polypeptide and a method of producing salmonid alphavirus neutralizing antibodies.

Abstract: The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.

Abstract: The present inventon relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.

Abstract: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.

Abstract: A method for pricing a productivity enhancing product or method, such as a feed additive, a fertilizer, or the like, that includes consideration of an expected or realized added benefit from the productivity enhancing product or method to an end user and the price that is expected to be received or has been received by the end user. Programs and systems with which such a pricing method are used are also disclosed.

Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Abstract: This invention relates to benzimidazole carbamates and (thio)carbamates corresponding to Formula I: Here, X1 and X2 are independently O or S, wherein at least one of X1 and X2 is O; Y1 and Y2 are independently O or S, wherein at least one of Y1 and Y2 is O; R1 is alkyl having from 1-4 carbon atoms; R2, R3, and R4 are independently hydrogen or a cation; R5 and R6 are independently hydrogen, halogen, alkyl (having from 1-8 carbon atoms), —OR7, —SR8, —CO—R9, —OSO2—Ar, or —S(O)R10; R7 is alkyl having from 1-8 carbon atoms; R8 is alkyl (having from 1-8 carbon atoms) or aryl; R9 is alkyl (having from 1-8 carbon atoms), cycloalkyl (having from 3-6 carbon atoms), or aryl; Ar is aryl; and R10 is alkyl (having from 1-8 carbon atoms) or aryl. The compounds generally are soluble and stable in water, and have antiparasitic (particularly anthelmintic) activity in vivo that is comparable to known water-insoluble benzimidazole carbamates (e.g., albendazole and fenbendazole).

Abstract: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

Abstract: Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer capsid coding region of a first FMDV strain, which has previously been shown to be an effective vaccine strain, with the outer capsid coding region of a second FMDV strain. The outer capsid coding region of the second FMDV strain is also modified to introduce a heparan sulphate proteoglycan (HSPG) binding site. The chimeric viruses are then used as seed viruses in the production of inactivated vaccine antigens which have been tailored for specific outbreak situations or locality. The invention also relates to the product of expression of the chimeric FMD viruses and to uses therefor, such as to form antigenic, immunological or vaccine compositions for prevention of FMD.

Abstract: The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test kits and to the use of said bacterium.

Abstract: Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.

Abstract: The present invention provides a new chicken astrovirus (CAstV). This chicken astrovirus (CAstV-2) is immunologically distinct from known avian astroviruses and can be used to prepare vaccines.

Abstract: A pharmaceutical composition for intramammary administration to a nonhuman mammal comprising an antibacterial agent and prednisolone, wherein the composition comprises at least 20 mg of prednisolone, and its use for the treatment of clinical mastitis.

Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.

Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.

Abstract: The present invention relates to veterinary immunology, namely to the immunological response of fish to a virus. More specifically, the invention provides an epitope of salmonid alphaviruses which epitope is capable of inducing a virus neutralising immune response. In particular the invention relates to a polypeptide comprising a certain amino acid sequence, a protein comprising such polypeptide, to a carrier comprising such protein, and to a method of producing antibodies. Further the invention relates to a nucleic acid encoding such polypeptide or such protein, and to a carrier comprising such a nucleic acid. Also, the invention relates to a vaccine and a diagnostic kit comprising such a polypeptide, protein, carrier, or nucleic acid.